Our Webinars

The Progression of Targeted Therapies: Addressing & Surmounting Complexities in Clinical Development

x

Synteract Oncology Clinical Trial Leadership

Deb Kientop, MBA
Vice President, Oncology

  • Deb Kientop, MBA brings over 25 years of experience in oncology drug development, starting in the cancer research labs at the University of Wisconsin, and moving into business development, medical affairs and clinical development roles within pharma and CRO. Her career has included thought leader engagement, product lifecycle planning, strategy development and execution for proposals and bid defenses, and corporate strategy and alliance management. Through her work with oncology investigators and patient advocacy organizations, she has been able to incorporate insights into patient-centric development strategies. Deb is also a published author and cancer patient advocate.
  • Prior to joining Synteract, Deb was the Vice President of Life Sciences at Inteliquet, a healthcare technology company. Previously, she held senior director strategy positions at two large CROs, as well as numerous biopharmaceutical organizations including MedImmune, MGI Pharma, and Eisai.
  • Deb holds a Bachelor of Science in Pharmacology and Toxicology, and a Master of Business Administration from the University of Wisconsin.
Contact us to find out more about our Oncology expertise and experience

Navigating Challenges in Dermatology Clinical Trials: Key Considerations

Date: Monday, April 27, 2020
Time: 11am EDT(NA) / 4pm BST (UK) / 5pm CEST (EU-Central)
Length: 60 minutes

REGISTER

Targeted therapies are currently the focus of much anti-cancer drug development. They are a cornerstone of precision medicine, using information about a person’s genes and proteins to prevent, diagnose and treat disease. While these therapies show great promise, they are also very complex. These immuno-oncology and cytostatic treatments often require different assumptions and factors to be tested compared to traditional, early safety-based trials for cytotoxic agents. Clinical trial design is a critical factor that can make or break success. Careful foresight in initial stages can impact data quality and trial duration.

This webinar will address leading therapies in novel oncology trials. It will provide an in-depth perspective on what drug developers can do to find the right patients. It will offer insights into just how important biomarkers and companion diagnostics may be in targeted therapy clinical trials.

Attendees will gain important insights from experts developing some of the most innovative oncology clinical trials today.

Key takeaways will include:

  • The current landscape and direction of novel oncology therapies
  • Evaluating and selecting the optimum trial design for targeted therapies such as immunotherapy, monoclonal antibodies, and gene therapy
  • Feasibility considerations, including advancements in resourcing and technology to help find and recruit patients and the increasing impact of COVID-19
  • The significance biomarkers and companion diagnostics play in the development of targeted therapies

Speaker:

  • Deb Kientop, MBA, Vice President, Oncology Development, Synteract
Looking for a previous webinar? Go to our Webinars Archive arrow
x

Submit RFI / RFP

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Synteract General Medicince Clinical Trial Leadership

Linda RawlingsContact us to find out more about our General Medicine expertise and experience

Linda Rawlings, MSc, FIBMS
VP General Medicine

Contact us to find out more about our General Medicine expertise and experience
x

Synteract Rare, Orphan, & Pediatric Diseases Clinical Trial Leadership

Lisa DilworthContact us to find out more about our Pediatric and Rare and Orphan Diseases expertise and experience

Lisa Dilworth
VP, Rare, Orphan, & Pediatrics

Contact us to find out more about our Rare, Orphan, & Pediatric Diseases expertise and experience
x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required